CADRENAL THERAPEUTICS INC (CVKD) Stock News

USA - Nasdaq - NASDAQ:CVKD - US1276362076 - Common Stock

10.18 USD

-0.92 (-8.29%)

Last: 12/5/2025, 8:12:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CVKD Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

17 days ago - By: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

a month ago - By: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

3 months ago - By: Benzinga - Mentions: HSDT BBLG AQB SXTC ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

3 months ago - By: Stocktwits - Mentions: VTI IWC

News Image

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

a year ago - By: BusinessInsider

News Image

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

3 months ago - By: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

3 months ago - By: Benzinga - Mentions: CAMP KEQU BLRX VNRX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

6 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

6 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

7 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

7 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

8 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

9 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

9 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

10 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

10 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

a year ago - By: Cadrenal Therapeutics

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

a year ago - By: Cadrenal Therapeutics, Inc.

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

a year ago - By: InvestorPlace

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

a year ago - By: Cadrenal Therapeutics, Inc. - Mentions: ABT

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024